Jazz Pharmaceuticals

About

Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments.

Palo Alto,California,United States
501 - 1000
https://www.jazzpharma.com/

Highlights

Details

Last Funding Type: Post-IPO Equity
Last Funding Money Raised: $6.99M
Industries: Biotechnology,Health Care,Pharmaceutical
Founded date: Jan 1, 2003
Number Of Employee: 501 - 1000
Operating Status: Active
Stock Symbol: nasdaq:JAZZ
Legal Name: Jazz Pharmaceuticals, Inc.
Also Known As: Jazz Pharmaceuticals plc

Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. Jazz Pharmaceuticals focuses on identifying, developing, and commercializing products for neurology and psychiatry primarily in the United States. Its products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Cystadane for the treatment of homocystinuria, an inherited metabolic disease; and Antizol to treat ethylene glycol and methanol poisoning. Its late-stage product candidates comprise Luvox CR, an extended-release formulation of fluvoxamine, a selective serotonin reuptake inhibitor, which is used for the treatment of obsessive-compulsive disorder and social anxiety disorder; and JZP-6, a liquid dosage form of sodium oxybate in Xyrem, for the treatment of fibromyalgia syndrome.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

7

$2.06B

Jazz Pharmaceuticals has raised a total of $2.06B in funding over 2 rounds. Their latest funding was raised on Apr 22, 2021 from a Post-IPO Debt round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Apr 22, 2021	Post-IPO Debt	$1.50B	—	—	—	Detail
Dec 7, 2009	Post-IPO Debt	$120M	—	—	—	Detail
Jul 8, 2009	Post-IPO Equity	$6.99M	1	Longitude Capital	—	Detail
May 8, 2008	Post-IPO Equity	$75M	1	—	—	Detail
May 31, 2007	IPO	$108M	—	—	—	Detail

Investments

Number of Investments

Number of Lead Investments

6

3

Jazz Pharmaceuticals has made 6 investments. Their most recent investment was on Dec 31, 2021, when Casa raised $21M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Dec 31, 2021 Casa	Series A	$21M	Bitcoin	—
Jul 29, 2021 Onera Health	Series B	€10.50M	Health Diagnostics	—
Jul 29, 2021 Onera Health	Series B	€10.50M	Health Care	—
Apr 24, 2019 Onera Health	Series A	€8.16M	Health Care	Yes
Apr 23, 2019 Onera Health	Series A	$9.30M	Health Diagnostics	Yes

Investors

Number of Lead Investors

Number of Investors

2

12

Jazz Pharmaceuticals is funded by 12 investors. Longitude Capital and Kohlberg Kravis Roberts are the most recent investors.

Investor Name	Lead Investor	Funding Round
Longitude Capital	Yes	Post-IPO Equity
Kohlberg Kravis Roberts	Yes	Series B
Kingsbridge Capital	—	Post-IPO Equity
Adams Street Partners	—	Series B
Beecken Petty O'Keefe & Company	—	Series B
EGS Healthcare Capital Partners	—	Series B
Golden Gate Capital	—	Series B
Lehman Brothers	—	Series B
Prospect Venture Partners	—	Series B
Thoma Cressey Equity Partners	—	Series B

Employee Profiles

Number of Employee Profiles

22

Jazz Pharmaceuticals has 22 current employee profiles, including Board member Elmar Schnee

Board member

Board member

Advisor

Employee

Executive

Acquisition

Jazz Pharmaceuticals has acquired 9 organizations. Their most recent acquisition was Orphan Medical on Apr 19, 2005. They acquired Orphan Medical for $122.60M.

Date Company Name	Industry	Acquisition Type	Price
Apr 19, 2005 Orphan Medical	Health Care	acquisition	$ 122.60M	Detail
Sep 19, 2011 Azur Pharma	Biotechnology	acquisition	—	Detail
Apr 26, 2012 EUSA Pharma	Biotechnology	—	$ 650M	Detail
Dec 19, 2013 Gentium	Biotechnology	—	—	Detail
May 11, 2016 Amolyt Pharma	Biotechnology	acquisition	$ 20.50M	Detail